Kyungdong Pharmaceutical has been selected as the lead research institute for the national project on the localization of essential medicines, which is overseen by the Ministry of Food and Drug Safety and the Korea Health Industry Development Institute.


Kyungdong Pharmaceutical Selected for National Essential Medicine Localization Project: "High-Purity API Synthesis Technology Recognized" View original image

On May 26, Kyungdong Pharmaceutical announced that, together with its joint research institute PTK Bio, it will work on the localization of raw material synthesis technology and development of finished formulations for three products: propranolol, vandetanib, and dextromethorphan·quinidine.


The domestic essential medicines market faces urgent supply chain stabilization issues due to low profitability and high dependence on imports. In particular, propranolol, used for infantile hemangioma, has experienced supply disruptions due to impurity detection issues. Vandetanib, a treatment for medullary thyroid cancer, and dextromethorphan·quinidine, used for pseudobulbar affect, are both 100% dependent on imports.


Kyungdong Pharmaceutical plans to localize high-purity raw material synthesis technology by applying Quality by Design (QbD) principles, enabling fundamental control of impurities such as nitrosamines from the manufacturing stage. Through this, the company aims to secure essential medicine raw material synthesis technology and gradually establish a system for the supply of high-quality raw materials. In the long term, by building a related production base from raw materials to finished medicines, the company intends to establish a stable supply system for essential medicines.



A Kyungdong Pharmaceutical representative stated, "Establishing a stable supply system in the field of essential medicines, where profitability is low and supply maintenance is difficult, is an important social responsibility for pharmaceutical companies," adding, "The selection for this national project recognizes Kyungdong Pharmaceutical's technological capacity in high-purity API synthesis, regulatory expertise, and commitment to the stable supply of essential medicines."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing